Polaryx Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark one)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number:001-43080 Polaryx Therapeutics, Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 1, 2026, the registrant had 47,343,297 shares of common stock, $0.0001 par value per share, outstanding. Polaryx Therapeutics, Inc.Form 10-QFor the Fiscal Quarter Ended March 31, 2026 TABLE OF CONTENTS PART I. Financial Information1Item 1.Financial Statements(Unaudited)1Condensed Balance Sheets as of March 31, 2026 and December 31, 20251Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026and 20252Condensed Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026 and20253Condensed Statements of Cash Flows for the three months ended March 31, 2026 and 20254Notes to Condensed Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures about Market Risk27Item 4.Controls and Procedures27PART II. Other Information28Item 1.Legal Proceedings28Item 1A.Risk Factors28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds28Item 3.Defaults upon Senior SecuritiesItem 4.Mine Safety Disclosures28Item 5.Other Information28Item 6.Exhibits29Signatures30 Part I. FINANCIAL INFORMATION As used in this Quarterly Report, unless the context otherwise requires, references to “we,” “us,” “our,” the “Company,”“Polaryx” and similar references refer to Polaryx Therapeutics, Inc. Additionally, references to our “Board” refer to the board ofdirectors of Polaryx Therapeutics, Inc. POLARYX THERAPEUTICS, INC.CONDENSED BALANCE SHEETS(Unaudited)(In thousands, except per share and share amounts) POLARYX THERAPEUTICS, INC.CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited, in thousands, except per share and share amounts) POLARYX THERAPEUTICS, INC.CONDENSED STATEMENTS OF CASH FLOWS(Unaudited, in thousands) POLARYX THERAPEUTICS, INC.NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS 1. Nature of the Business and Basis of Presentation Polaryx Therapeutics, Inc. (the “Company”) is a clinical-stage biotechnology company committed to the discovery,development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders. On October24, 2025, the Company completed the redomestication to convert into a Nevada corporation from a Wyoming corporation. Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted inthe UnitedStates (“U.S.GAAP”). There is no difference between net loss and comprehensive loss in these financial statements. The condensed financial statements for the three month period ended March31, 2026 are unaudited, and inthe opinion of management, contain all adjustments necessary for a fair presentation of the condensed financial statements. Suchadjustments consist solely of normal recurring items. Interim results are not necessarily indicative of results for a full year or anysubsequent interim period. The condensed financial statements and notes are prepared in accordance with U.S.GAAP and do notcontain certain information included in the annual financial statements and acc